VGKVanguard FTSE Europe ETF


$ 68.38 $ 0.56 (0.83 %)    

Friday, 05-Jul-2024 15:59:43 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 68.39
$ 68.50
$ 68.37 x 400
$ 68.38 x 400
$ 67.93 - $ 68.50
$ 53.54 - $ 69.61
1,281,599
na
na
$ 0.97
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://x.com/EpicNewsroom/status/1809179988131713090

 asia-in-red-uk-advances-as-labour-party-wins-majority-while-us-dollar-dips-ahead-of-payrolls-data---global-markets-today-while-us-slept

US stock markets closed mixed on July 3rd. S&P 500 and Nasdaq reached record highs, while Dow Jones fell. Asian markets als...

Core News & Articles

- Reuters Citing Politico

Core News & Articles

- Reuters Citing TV Stream

Core News & Articles

- Bloomberg

Core News & Articles

- Bloomberg

Core News & Articles

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...

Core News & Articles

https://www.reuters.com/business/aerospace-defense/boeing-brief-european-regulators-new-production-plans-after-737-max-panel-20...

Core News & Articles

- Reuters Citing Sources

Core News & Articles

https://www.reuters.com/world/us/trump-reviews-plan-halt-us-military-aid-ukraine-unless-it-negotiates-peace-with-2024-06-25/Two...

Core News & Articles

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3GAITHERSBURG, Md., Ju...

Core News & Articles

GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a set...

Core News & Articles

https://ec.europa.eu/commission/presscorner/detail/en/ip_24_3433

Core News & Articles

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...